Jefferies Group’s Vaxcyte PCVX Stock Holding History

Jefferies Group’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,000	Closed	-$266K	–	1893
2020 Q4	$266K	Buy	+10,000	New	+$372K	﹤0.01%	1308

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Group's PCVX Position: Q1 2021 in Review

Jefferies Group sold out of Vaxcyte (PCVX) in Q1 2021, closing a stake of 10,000 shares — an estimated $266K sold.

Jefferies Group first reported a position in PCVX in Q4 2020 and held it in 1 quarter. The position peaked at $266K in Q4 2020. 74 funds tracked by Wall St. Rank hold PCVX as of Q1 2021.

Jefferies Group reported no remaining Vaxcyte position as of Q1 2021 after selling out during the quarter.
Jefferies Group sold 10,000 Vaxcyte shares in Q1 2021, an estimated $266K.
Jefferies Group first reported a position in Vaxcyte in Q4 2020 and held it in 1 quarter.
Jefferies Group's Vaxcyte position peaked at $266K in Q4 2020.
74 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.